Goldman Sachs Group Inc C4 Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 505,852 shares of CCCC stock, worth $1.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
505,852
Previous 737,835
31.44%
Holding current value
$1.89 Million
Previous $3.41 Million
15.4%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CCCC
# of Institutions
129Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$25.7 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$24.7 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$21.2 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$18.2 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$17 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $183M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...